Kayla Janto1, J Roxanne Prichard1, Snigdha Pusalavidyasagar2. 1. Department of Psychology, University of St. Thomas, St. Paul, Minnesota. 2. Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Minnesota, Minneapolis, Minnesota.
Abstract
STUDY OBJECTIVES: Current pharmacological options for the treatment of insomnia insufficiently meet the needs of all insomnia patients. Approved treatments are not consistently effective in improving sleep onset and sleep maintenance, while also having complicated safety profiles. These limitations highlight the unmet need for additional medications and treatment strategies. Initial research suggests that the dual orexin receptor antagonists (DORAs) may offer an additional pharmaceutical option to treat insomnia in some patients. METHODS: We reviewed the existing literature on dual orexin receptor antagonists in PubMed databases using the search terms "orexin receptor antagonist," "almorexant" "filorexant," "lembroexant" and "suvorexant"; searches were limited to English language primary research articles, clinical trials, and reviews. RESULTS: Targeting the orexin receptor system for treatment of insomnia offers an additional and alternative pharmacological approach to more common gamma aminobutyric acid agonist sedative hypnotic treatment. Effectiveness is not well established in the current literature; however, the literature does suggest efficacy. Preclinical reports also suggest the potential for treatment in individuals with comorbid Alzheimer disease and insomnia. CONCLUSIONS: DORAs offer an additional treatment option for insomnia. More clinical trials are needed to robustly evaluate their safety and effectiveness in several subclasses of individuals with insomnia. Given the published literature, head-to-head comparisons to existing treatment for insomnia are warranted.
STUDY OBJECTIVES: Current pharmacological options for the treatment of insomnia insufficiently meet the needs of all insomniapatients. Approved treatments are not consistently effective in improving sleep onset and sleep maintenance, while also having complicated safety profiles. These limitations highlight the unmet need for additional medications and treatment strategies. Initial research suggests that the dual orexin receptor antagonists (DORAs) may offer an additional pharmaceutical option to treat insomnia in some patients. METHODS: We reviewed the existing literature on dual orexin receptor antagonists in PubMed databases using the search terms "orexin receptor antagonist," "almorexant" "filorexant," "lembroexant" and "suvorexant"; searches were limited to English language primary research articles, clinical trials, and reviews. RESULTS: Targeting the orexin receptor system for treatment of insomnia offers an additional and alternative pharmacological approach to more common gamma aminobutyric acid agonist sedative hypnotic treatment. Effectiveness is not well established in the current literature; however, the literature does suggest efficacy. Preclinical reports also suggest the potential for treatment in individuals with comorbid Alzheimer disease and insomnia. CONCLUSIONS: DORAs offer an additional treatment option for insomnia. More clinical trials are needed to robustly evaluate their safety and effectiveness in several subclasses of individuals with insomnia. Given the published literature, head-to-head comparisons to existing treatment for insomnia are warranted.
Authors: David Michelson; Ellen Snyder; Erin Paradis; Mary Chengan-Liu; Duane B Snavely; Jill Hutzelmann; James K Walsh; Andrew D Krystal; Ruth M Benca; Martin Cohn; Christopher Lines; Thomas Roth; W Joseph Herring Journal: Lancet Neurol Date: 2014-03-27 Impact factor: 44.182
Authors: Ronald C Kessler; Patricia A Berglund; Catherine Coulouvrat; Goeran Hajak; Thomas Roth; Victoria Shahly; Alicia C Shillington; Judith J Stephenson; James K Walsh Journal: Sleep Date: 2011-09-01 Impact factor: 5.849
Authors: Thomas Roth; Catherine Coulouvrat; Goeran Hajak; Matthew D Lakoma; Nancy A Sampson; Victoria Shahly; Alicia C Shillington; Judith J Stephenson; James K Walsh; Ronald C Kessler Journal: Biol Psychiatry Date: 2010-12-31 Impact factor: 13.382
Authors: Thomas C Neylan; Anne Richards; Thomas J Metzler; Leslie M Ruoff; Jonathan Varbel; Aoife O'Donovan; Melinda Sivasubramanian; Terri Motraghi; Jennifer Hlavin; Steven L Batki; Sabra S Inslicht; Kristin Samuelson; Stephen R Morairty; Thomas S Kilduff Journal: Sleep Date: 2020-10-13 Impact factor: 5.849
Authors: Philip Scheltens; Bart De Strooper; Miia Kivipelto; Henne Holstege; Gael Chételat; Charlotte E Teunissen; Jeffrey Cummings; Wiesje M van der Flier Journal: Lancet Date: 2021-03-02 Impact factor: 79.321